Gambro invests SEK 150 million in increased production

Gambro invests SEK 150 million in increased production Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it will invest about SEK 150 million in increased production capacity for powder cartridges for dialysis. Gambro in Lund, Sweden will increase its capacity for powder cartridges, which is an important part of Gambro's ongoing strategic investment in advanced on-line systems for production of dialysis fluids. This will enable Gambro to meet the continued strong demand for BiCart and other specialized powder cartridges. In this area Gambro has a leading position on the market. "It is very encouraging that the sales of BiCart and other cartridge products continues to increase", says Sören Mellstig, Executive Vice President of Gambro and responsible for the Renal Care Products Business Area. "Gambro's system eliminates a labor-intensive and complex handling of concentrates at the dialysis clinic. This also improves quality and efficiency. We have a very strong position on the market and through this investment in increased capacity we will in a few years be able to double our production." Liquids and solutions are needed when giving dialysis treatment to patients with kidney failure. Through several innovations Gambro has been able to radically simplify the production and usage of these liquids and solutions when treating patients in dialysis clinics. With the help of powder cartridges these solutions are produced on-line in the dialysis machine and thus greatly simplifying this part of the treatment procedure. The first BiCart product was introduced in 1987. Today Gambro's on-line system BiCart Select among other products also includes SelectCart and CleanCart. Systems and products are developed by Gambro in Lund, Sweden where today the company's global center of excellence for development and production of BiCart and other powder cartridges is located. For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Sören Mellstig, Executive Vice President, Responsible for Renal Care Products, tel. +46-8-613 65 81, +46-70-513 65 81 Tim Schoenberg, Vice President, US Investor Relations Manager, tel. +1-949- 425-2185 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 42,000 patients in 565 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/09/23/19990923BIT00270/bit0001.doc http://www.bit.se/bitonline/1999/09/23/19990923BIT00270/bit0002.pdf

About Us

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Subscribe